File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Case series: MRD negativity assessment using 11C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma

TitleCase series: MRD negativity assessment using 11C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma
Authors
Keywords3-weekly daratumumab
C-11-Acetate PET
MRD negativity
newly diagnosed multiple myeloma
quadruplet induction
Issue Date2021
PublisherSage Publications: Open Access Journals. The Journal's web site is located at http://tah.sagepub.com/
Citation
Therapeutic Advances in Hematology, 2021, v. 12, p. article no. 20406207211030369 How to Cite?
AbstractComplete response (CR) is an important favorable factor for survival in multiple myeloma (MM). However, CR patients continue to relapse, especially in the presence of minimal residual disease (MRD). Bone marrow (BM) MRD is predictive of progression-free survival (PFS) in MM. However, myeloma outside the BM aspiration site may result in subsequent relapse despite MRD-negativity. Therefore, positron emission tomography-computed tomography (PET-CT) based on F-fluorodeoxyglucose (FDG) is a complementary tool to monitor residual disease in MM. However, FDG may miss myeloma lesions that are not FDG-avid. On the other hand, C-11-Acetate (ACT) has been found to be a more sensitive and specific tracer than FDG in MM. Recently, the addition of daratumumab to bortezomib, thalidomide, dexamethasone (VTd) or bortezomib, lenalidomide, dexamethasone (VRd) backbone has been proven to improve outcomes. Herein, we report three newly-diagnosed MM patients achieving deep responses with imaging CR using ACT PET in addition to conventional immunofixation CR and MRD-negative CR after a 3-weekly daratumumab-based quadruplet induction regimen.
Persistent Identifierhttp://hdl.handle.net/10722/307889
ISSN
2023 Impact Factor: 3.4
2023 SCImago Journal Rankings: 1.258
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNgai, C-
dc.contributor.authorKumar, S-
dc.contributor.authorHo, GCL-
dc.contributor.authorChen, SR-
dc.contributor.authorChim, JCS-
dc.date.accessioned2021-11-12T13:39:22Z-
dc.date.available2021-11-12T13:39:22Z-
dc.date.issued2021-
dc.identifier.citationTherapeutic Advances in Hematology, 2021, v. 12, p. article no. 20406207211030369-
dc.identifier.issn2040-6207-
dc.identifier.urihttp://hdl.handle.net/10722/307889-
dc.description.abstractComplete response (CR) is an important favorable factor for survival in multiple myeloma (MM). However, CR patients continue to relapse, especially in the presence of minimal residual disease (MRD). Bone marrow (BM) MRD is predictive of progression-free survival (PFS) in MM. However, myeloma outside the BM aspiration site may result in subsequent relapse despite MRD-negativity. Therefore, positron emission tomography-computed tomography (PET-CT) based on F-fluorodeoxyglucose (FDG) is a complementary tool to monitor residual disease in MM. However, FDG may miss myeloma lesions that are not FDG-avid. On the other hand, C-11-Acetate (ACT) has been found to be a more sensitive and specific tracer than FDG in MM. Recently, the addition of daratumumab to bortezomib, thalidomide, dexamethasone (VTd) or bortezomib, lenalidomide, dexamethasone (VRd) backbone has been proven to improve outcomes. Herein, we report three newly-diagnosed MM patients achieving deep responses with imaging CR using ACT PET in addition to conventional immunofixation CR and MRD-negative CR after a 3-weekly daratumumab-based quadruplet induction regimen.-
dc.languageeng-
dc.publisherSage Publications: Open Access Journals. The Journal's web site is located at http://tah.sagepub.com/-
dc.relation.ispartofTherapeutic Advances in Hematology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subject3-weekly daratumumab-
dc.subjectC-11-Acetate PET-
dc.subjectMRD negativity-
dc.subjectnewly diagnosed multiple myeloma-
dc.subjectquadruplet induction-
dc.titleCase series: MRD negativity assessment using 11C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma-
dc.typeArticle-
dc.identifier.emailChim, JCS: jcschim@HKUCC-COM.hku.hk-
dc.identifier.authorityChim, JCS=rp00408-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1177/20406207211030369-
dc.identifier.pmid34616538-
dc.identifier.pmcidPMC8488511-
dc.identifier.scopuseid_2-s2.0-85116334450-
dc.identifier.hkuros329774-
dc.identifier.volume12-
dc.identifier.spagearticle no. 20406207211030369-
dc.identifier.epagearticle no. 20406207211030369-
dc.identifier.isiWOS:000703775100001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats